{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:50:34Z","timestamp":1765475434231,"version":"3.48.0"},"reference-count":8,"publisher":"Innovative Healthcare Institute","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>At present, for patients with metastatic and castration-resistant prostate cancer, European Society for Medical Oncology and National Comprehensive Cancer Network guidelines recommend enzalutamide (E) or abiraterone (A). There are still a few studies comparing both drugs in a real-world setting, thus, in this article, we discuss an outcomes management methodology, supporting the follow-up of patients. This involves measuring relevant baseline traits and outcomes, such as overall survival (OS), treatment duration, patient-reported outcomes, and adverse events. We include 38 men in the A group and 15 in the E group. When comparing the survival of both drugs, both present similar OS. Regarding the quality-of-life analysis (QoL) with EPIC26, reported Standard QoL score was 58.3% in our patients, which was in line with the European Organization for the Research and Treatment of Cancer reference. As a result, by showing that we can capture the distinctive clinical benefits of A and E, and that patient-reported outcomes can be systematically collected for more than 2 years per living patient, we can now incorporate these findings in clinical discussions, risk-sharing agreements, or policy-level arguments.<\/jats:p>","DOI":"10.36401\/jqsh-19-39","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T16:52:05Z","timestamp":1596732725000},"page":"65-68","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.36401","volume":"3","author":[{"given":"Pedro","family":"Cardoso","sequence":"first","affiliation":[{"name":"Luz Sa\u00fade, Lisbon, Portugal"}]},{"given":"C.","family":"Santos","sequence":"additional","affiliation":[{"name":"Luz Sa\u00fade, Lisbon, Portugal"}]},{"given":"F.","family":"Costa","sequence":"additional","affiliation":[{"name":"Luz Sa\u00fade, Lisbon, Portugal"}]},{"given":"Francisco","family":"Rocha-Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Luz Sa\u00fade, Lisbon, Portugal"},{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"}]}],"member":"22027","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"2021072121012437000_i2589-9449-3-2-65-b01","unstructured":"Cancer Data-Portugal.\n\t\t\t\t\tThe Global Cancer Observatory.\n\t\t\t\t\t2019:1.https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/620-portugal-fact-sheets.pdf. Accessed January 27, 2020."},{"key":"2021072121012437000_i2589-9449-3-2-65-b02","unstructured":"Miranda\n              N,\n            \n            \n              Portugal\n              C,\n            \n            \n              Nogueira\n              P,\n            \n            et al.\n\t\t\t\t\t\n          Portugal \u2013 Doen\u00e7as Oncol\u00f3gicas em n\u00fameros.\n\t\t\t\t\tDirec\u00e7\u00e3o Geral da Sa\u00fade.\n\t\t\t\t\t2016:39.https:\/\/www.dgs.pt\/estatisticas-de-saude\/estatisticas-de-saude\/publicacoes\/portugal-doencas-oncologicas-em-numeros-2015-pdf.aspx. Accessed January 27, 2020."},{"key":"2021072121012437000_i2589-9449-3-2-65-b03","doi-asserted-by":"crossref","unstructured":"Rawla\n              P.\n            \n          \n          Epidemiology of prostate cancer.\n\t\t\t\t\tWorld J Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t63\u2013\n\t\t\t\t\t89.","DOI":"10.14740\/wjon1191"},{"key":"2021072121012437000_i2589-9449-3-2-65-b04","doi-asserted-by":"crossref","unstructured":"Mohler\n              J,\n            \n            \n              Antonarakis\n              E,\n            \n            \n              Armstrong\n              A,\n            \n            et al.\n\t\t\t\t\t\n          Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology.\n\t\t\t\t\tJ Natl Compr Canc Netw.\n\t\t\t\t\t2019;\n\t\t\t\t\t17:\n\t\t\t\t\t479\u2013\n\t\t\t\t\t505.","DOI":"10.6004\/jnccn.2019.0100"},{"key":"2021072121012437000_i2589-9449-3-2-65-b05","doi-asserted-by":"crossref","unstructured":"Parker\n              C,\n            \n            \n              Gillessen\n              S,\n            \n            \n              Heidenreich\n              A,\n            \n            \n              Horwich\n              A.\n            \n          \n          Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t26:\n\t\t\t\t\tv69\u2013\n\t\t\t\t\tv77.","DOI":"10.1093\/annonc\/mdv222"},{"key":"2021072121012437000_i2589-9449-3-2-65-b06","doi-asserted-by":"crossref","unstructured":"Shore\n              N,\n            \n            \n              Saltzstein\n              D,\n            \n            \n              Sieber\n              P,\n            \n            et al.\n\t\t\t\t\t\n          Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).\n\t\t\t\t\tClin Genitourin Cancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t17:\n\t\t\t\t\t457\u2013\n\t\t\t\t\t463.e6.","DOI":"10.1016\/j.clgc.2019.07.017"},{"key":"2021072121012437000_i2589-9449-3-2-65-b07","doi-asserted-by":"crossref","unstructured":"Hara\n              I,\n            \n            \n              Yamashita\n              S,\n            \n            \n              Nishizawa\n              S,\n            \n            \n              Kikkawa\n              K,\n            \n            \n              Shimokawa\n              T,\n            \n            \n              Kohjimoto\n              Y.\n            \n          \n          Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer: protocol for a multicenter randomized phase 3 trial.\n\t\t\t\t\tJMIR Res Protoc.\n\t\t\t\t\t2018;\n\t\t\t\t\t7:\n\t\t\t\t\te11191.","DOI":"10.2196\/11191"},{"key":"2021072121012437000_i2589-9449-3-2-65-b08","unstructured":"Scott\n              N,\n            \n            \n              Fayers\n              P,\n            \n            \n              Aaronson\n              N,\n            \n            et al.\n\t\t\t\t\t\n          EORTC QLQ C30-Reference Values.\n\t\t\t\t\tEORTC Quality of Life Group.\n\t\t\t\t\t2008:286.https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf. Accessed January 27, 2020."}],"container-title":["Global Journal on Quality and Safety in Healthcare"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JQSH\/article-pdf\/3\/2\/65\/2870805\/i2589-9449-3-2-65.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JQSH\/article-pdf\/3\/2\/65\/2870805\/i2589-9449-3-2-65.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:47:30Z","timestamp":1765475250000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals.kglmeridian.com\/view\/journals\/jqsh\/3\/2\/article-p65.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,21]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jqsh-19-39","relation":{},"ISSN":["2589-9449","2666-2353"],"issn-type":[{"type":"electronic","value":"2589-9449"},{"type":"print","value":"2666-2353"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}